Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Stock Information for Aeterna Zentaris Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aeterna Zentaris Inc.

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, EVFM, AEZS, HOLI
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Aeterna Zentaris Inc. Merger
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RAIN, BLBX, AEZS
AEZS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aeterna Zentaris Inc. Is Fair to Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.